The Lipoxygenases (LOXs) are a class of enzymes that convert arachidonic, linoleic, and other polyunsaturated fatty acid into biologically active metabolites involved in the inflammatory and immune responses. Recent evidences indicate that LOXs and the signaling pathways that are involved in their activation are also important for carcinogenesis and tumor progression. LOXs should therefore receive as much attention from cancer researchers as it has already from immunologists. In this article, we will review some evidence that the LOXs pathways affect several aspects of lung, pancreatic and prostate cancer progression. Moreover, we discuss how this new perspective on the roles of LOXs and their metabolites can have important implications to cancer therapy.